Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma

NCT04910022 is registered in ClinicalTrials.gov with Nerviano Medical Sciences as lead sponsor.

NCT NCT04910022
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04910022 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients With Recurrent Glioblastoma
Lead sponsor
Nerviano Medical Sciences
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 1, 2021
Completion date
September 7, 2027
Enrollment
150 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse glioma, glioblastoma